Literature DB >> 14007905

Comparison of psilocin with psilocybin, mescaline and LSD-25.

A B WOLBACH, E J MINER, H ISBELL.   

Abstract

Entities:  

Keywords:  HALLUCINOGENS/pharmacology; LYSERGIC ACID DIETHYLAMIDE/pharmacology; MERCURY/pharmacology

Mesh：

Substances：

Year:  1962        PMID： 14007905     DOI： 10.1007/BF00412109

Source DB:  PubMed          Journal:  Psychopharmacologia


× No keyword cloud information.
  7 in total

1.  Cross tolerance between mescaline and LSD-25, with a comparison of the mescaline and LSD reactions.

Authors:  A B WOLBACH; H ISBELL; E J MINER
Journal:  Psychopharmacologia       Date:  1962-03-12

2.  The enzymic dephosphorylation and oxidation of psilocybin and psilocin by mammalian tissue homogenates.

Authors:  A HORITA; L J WEBER
Journal:  Biochem Pharmacol       Date:  1961-07       Impact factor: 5.858

3.  [Elucidation of the structure and the synthesis of psilocybin].

Authors:  A HOFMANN; A FREY; H OTT; T PETR ZILKA; F TROXLER
Journal:  Experientia       Date:  1958-11-15

4.  [Identification of psilocin].

Authors:  A HOFMANN; F TROXLER
Journal:  Experientia       Date:  1959-03-15

5.  Comparison of the reactions induced by psilocybin and LSD-25 in man.

Authors:  H ISBELL
Journal:  Psychopharmacologia       Date:  1959

6.  Bioassays and mathematics.

Authors:  J H GADDUM
Journal:  Pharmacol Rev       Date:  1953-03       Impact factor: 25.468

7.  Studies on lysergic acid diethylamide (LSD-25). I. Effects in former morphine addicts and development of tolerance during chronic intoxication.

Authors:  R E BELLEVILLE; H F FRASER; H ISBELL; C R LOGAN; A WIKLER
Journal:  AMA Arch Neurol Psychiatry       Date:  1956-11
  7 in total
  27 in total

1.  Effects of LSD-25 on avoidance behavior and locomotor activity in mice.

Authors:  C Castellano
Journal:  Psychopharmacology (Berl)       Date:  1979-04-11       Impact factor: 4.530

2.  Effects of mescaline and psilocin on acquisition, consolidation, and performance of light-dark discrimination in two inbred strains of mice.

Authors:  C Castellano
Journal:  Psychopharmacology (Berl)       Date:  1978-10-31       Impact factor: 4.530

3.  Indoles.

Authors: 
Journal:  Bull World Health Organ       Date:  1970       Impact factor: 9.408

4.  Mystical experiences occasioned by the hallucinogen psilocybin lead to increases in the personality domain of openness.

Authors:  Katherine A MacLean; Matthew W Johnson; Roland R Griffiths
Journal:  J Psychopharmacol       Date:  2011-09-28       Impact factor: 4.153

Review 5.  Human hallucinogen research: guidelines for safety.

Authors:  Mw Johnson; Wa Richards; Rr Griffiths
Journal:  J Psychopharmacol       Date:  2008-07-01       Impact factor: 4.153

6.  Psilocybin occasioned mystical-type experiences: immediate and persisting dose-related effects.

Authors:  Roland R Griffiths; Matthew W Johnson; William A Richards; Brian D Richards; Una McCann; Robert Jesse
Journal:  Psychopharmacology (Berl)       Date:  2011-06-15       Impact factor: 4.530

Review 7.  Clinical applications of hallucinogens: A review.

Authors:  Albert Garcia-Romeu; Brennan Kersgaard; Peter H Addy
Journal:  Exp Clin Psychopharmacol       Date:  2016-08       Impact factor: 3.157

8.  Psychedelic drugs: steric factors that predict psychotropic activity.

Authors:  S H Snyder; E Richelson
Journal:  Proc Natl Acad Sci U S A       Date:  1968-05       Impact factor: 11.205

9.  A relationship between the hallucinogenic activity of drugs and their electronic configuration.

Authors:  S H Snyder; C R Merril
Journal:  Proc Natl Acad Sci U S A       Date:  1965-07       Impact factor: 11.205

Review 10.  The abuse potential of medical psilocybin according to the 8 factors of the Controlled Substances Act.

Authors:  Matthew W Johnson; Roland R Griffiths; Peter S Hendricks; Jack E Henningfield
Journal:  Neuropharmacology       Date:  2018-06-05       Impact factor: 5.250
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.